You didn't answer my question but I'll still try and answer yours. My OPINION only:
Elite would have its money better spent through R&D toward the ADF pipeline. That being said, the generic pipeline keeps it afloat in the meantime. It would be much easier for Elite to obtain additional generic products, say, by payment in shares. I'm not saying this is for sure what is about to happen but it wouldn't surprise me. It makes more sense and is more feasible for those shares to go to Nasrat for payment of said generic(s) than Teva or Allergen the companies.
Again, IF this were to occur, it just aligns Nasrat that much more with the success of the company, right? What does he stand to gain by acquiring all these shares and taking salary in shares if they never significantly appreciate in value?
News 
Market Data 
Discover 
